Welcome to our dedicated page for Geron news (Ticker: GERN), a resource for investors and traders seeking the latest updates and insights on Geron stock.
Geron Corporation (Nasdaq: GERN) is a commercial-stage biopharmaceutical company focused on blood cancers and myeloid hematologic malignancies through telomerase inhibition. News about Geron frequently centers on its first-in-class telomerase inhibitor RYTELO (imetelstat), which is approved in the United States and the European Union for certain adult patients with lower-risk myelodysplastic syndromes (LR-MDS) who have transfusion-dependent anemia.
On this page, readers can follow corporate announcements and scientific updates that shape the GERN investment story. Typical news items include financial guidance and quarterly results that discuss RYTELO net product revenue and operating expenses, strategic restructuring plans intended to support the company’s hematology focus, and details of equity grants made under Nasdaq inducement award rules. These disclosures provide insight into Geron’s commercial execution, cost structure and capital allocation.
Geron also issues frequent clinical and medical conference updates. Recent releases have highlighted data presented at the American Society of Hematology (ASH) Annual Meeting, including pooled analyses from the Phase 3 IMerge trial in LR-MDS, long-term outcomes data, and exploratory biomarker studies in myelofibrosis and advanced myelodysplastic neoplasms or acute myeloid leukemia. News about the IMpactMF Phase 3 trial in JAK-inhibitor relapsed/refractory myelofibrosis, as well as the IMbark, IMproveMF and IMpress studies, offers additional context on imetelstat’s development across myeloid malignancies.
Investors can also track leadership changes and investor relations events, such as executive appointments, board updates and participation in healthcare investor conferences. Together, these news items help explain how Geron is pursuing its stated priorities of driving RYTELO commercial growth, expanding access in LR-MDS markets outside the U.S. and advancing its pivotal myelofibrosis program. Bookmark this page to follow ongoing developments affecting GERN’s clinical programs, regulatory milestones, commercial performance and corporate strategy.
Geron (Nasdaq: GERN) announced that the National Comprehensive Cancer Network (NCCN) has updated its Clinical Practice Guidelines for Myelodysplastic Syndromes (MDS) to recommend RYTELO™ (imetelstat) as a Category 1 and 2A treatment for symptomatic anemia in lower-risk MDS patients. RYTELO is recommended as a Category 1 second-line treatment for both RS+ and RS- patients with serum EPO ≤500 mU/mL, and as a Category 2A first-line treatment for patients with serum EPO >500 mU/mL. This update follows the FDA's approval of RYTELO in June 2024 for treating adult patients with low- to intermediate-1 risk MDS with transfusion-dependent anemia. The company believes these updates will increase awareness and uptake of RYTELO as a new treatment option for eligible lower-risk MDS patients.
Geron (Nasdaq: GERN) announced that Anil Kapur, Executive Vice President, Corporate Strategy and Chief Commercial Officer, will depart the company on August 31, 2024. A search for a new Chief Commercial Officer is underway. In the interim, Andrew Grethlein, Ph.D., Executive Vice President, Chief Operating Officer, will lead the commercial organization, supported by Board member Dawn Carter Bir.
The company expressed confidence in the uptake of RYTELO™ in its first month of launch and the positive customer feedback. CEO John A. Scarlett thanked Kapur for his contributions over the past five years, particularly in defining RYTELO's potential market and building a strong commercial organization.
Geron (Nasdaq: GERN), a commercial-stage biopharmaceutical company, has announced that it will release its second quarter 2024 financial results and business highlights on Thursday, August 8, 2024. The company will issue a press release before the market opens, which will be available on their website. Additionally, Geron will host a conference call and webcast at 8:00 a.m. ET on the same day to discuss the financial results and business highlights. Interested parties can access the webcast by registering online through the provided link. An archive of the webcast will be available on the company's website for 30 days following the event.
Geron , a biopharmaceutical company, announced inducement grants under Nasdaq Listing Rule 5635(c)(4). The company granted non-statutory stock options for 222,660 shares to new employees as of June 19, 2024. The exercise price is $4.49 per share, equal to the closing price of Geron stock on the grant date. These options have a 10-year term and vest over four years, with 12.5% vesting after six months and the remainder vesting in equal installments over 42 months, subject to continued employment. The grants are part of Geron's 2018 Inducement Award Plan.
Geron has announced FDA approval for RYTELO™ (imetelstat), the first telomerase inhibitor, to treat adults with lower-risk myelodysplastic syndromes (MDS) suffering from transfusion-dependent anemia. The approval covers ESA ineligible and relapsed/refractory patients, regardless of ring sideroblast status. The IMerge Phase 3 clinical trial revealed significant improvements in transfusion independence and hemoglobin levels. The common Grade 3/4 adverse reactions were thrombocytopenia and neutropenia but were generally manageable. A conference call is scheduled for June 7, 2024, at 8 am ET to discuss these developments.
Geron (Nasdaq: GERN) announced the grant of non-statutory stock options to purchase 2,910,780 shares of common stock as inducements for newly hired employees. The options were granted on May 15, 2024, at an exercise price of $3.90 per share, matching the closing price on the grant date. The options, which have a 10-year term, will vest over four years, starting with 12.5% on the six-month anniversary of employment, followed by equal monthly installments over the next 42 months. These inducements are in line with Nasdaq Listing Rule 5635(c)(4) and Geron's 2018 Inducement Award Plan.
Geron (Nasdaq: GERN) reported financial results for the first quarter of 2024, including a net loss of $55.4 million and revenues of $304,000. The company has completed commercial team onboarding and is preparing for the potential U.S. launch of imetelstat pending FDA approval. The Phase 3 IMpactMF trial continues with updated timelines. Geron expects total operating expenses for fiscal year 2024 to be $270-280 million.
Summary not available.
Summary not available.
Summary not available.
FAQ
What is the current stock price of Geron (GERN)?
What is the market cap of Geron (GERN)?
